Insulet Reports Third Quarter 2026 Results
Article excerpt
Highlighted: the sentence this signal was extracted from
Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency 1 ) ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Recent Strategic Highlights: Received approval from the Board of Directors for a $1 billion share repurchase program. The Company expects to allocate approximately $400 million toward repurchases in the fourth quarter of 2026, funded with existing cash. This expanded authorization reflects Insulet's strong balance sheet and disciplined approach to capital deployment. "Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion," said Ashley McEvoy, President and CEO. "We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation. As we look ahead, the business is well positioned for durable, profitable growth. The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory." 1 See description of non-GAAP financial measures contained in...
Keep reading with a free account
The rest of this article, and every signal for Insulet, is in your free account.
